This joint guidance by the ECDC and EMCDDA aims to strengthen the evidence base for developing national strategies for preventing and controlling infections and infectious diseases among people who inject drugs.
This document is an update of the joint guidance that was published in 2011 by the European Centre for Disease Prevention and Control (ECDC) and the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA).
Prevalence data from sources such as population surveys can be a useful complement to case based surveillance data for hepatitis C. Case-based surveillance has limitations as most diagnosed cases are chronic in nature and detection of cases depends largely on testing practices. Prevalence data can therefore contribute towards a fuller understanding of the epidemiology of hepatitis C.
In 2021, 14 560 cases of hepatitis C were reported in 29 EU/EEA Member States. Excluding countries that only reported acute cases the number of cases (14 550 cases) corresponds to a crude rate of 4.1 cases per 100 000 population.
Viral hepatitis is an infection that causes inflammation of the liver. It can be caused by different viruses, including hepatitis B virus (HBV) and hepatitis C virus (HCV). Both HBV and HCV can cause acute and chronic infections and are leading causes of liver cirrhosis and hepatocellular carcinoma.